EA201492177A1 - CLEANING IURONAT-2-SULFATASE - Google Patents

CLEANING IURONAT-2-SULFATASE

Info

Publication number
EA201492177A1
EA201492177A1 EA201492177A EA201492177A EA201492177A1 EA 201492177 A1 EA201492177 A1 EA 201492177A1 EA 201492177 A EA201492177 A EA 201492177A EA 201492177 A EA201492177 A EA 201492177A EA 201492177 A1 EA201492177 A1 EA 201492177A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iuronat
sulfatase
cleaning
protein
present
Prior art date
Application number
EA201492177A
Other languages
Russian (ru)
Other versions
EA034549B1 (en
Inventor
Дэйв Николс
Original Assignee
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетик Терапис, Инк.
Publication of EA201492177A1 publication Critical patent/EA201492177A1/en
Publication of EA034549B1 publication Critical patent/EA034549B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Abstract

В настоящем изобретении, среди прочего, предложены усовершенствованные способы очистки белка I2S, полученного рекомбинантным способом, для ферментозаместительной терапии. Настоящее изобретение частично основано на неожиданном открытии, что рекомбинантный белок I2S может быть очищен от необработанного биологического материала, такого как содержащая I2S клеточная культуральная среда, при помощи способа, включающего применение всего лишь четырех хроматографических колонок.In the present invention, among other things, proposed improved methods for purification of the recombinantly produced I2S protein for enzyme replacement therapy. The present invention is based in part on the surprising discovery that recombinant I2S protein can be purified from untreated biological material, such as an I2S-containing cell culture medium, using a method involving the use of only four chromatographic columns.

EA201492177A 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase EA034549B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
EA201492177A1 true EA201492177A1 (en) 2015-06-30
EA034549B1 EA034549B1 (en) 2020-02-19

Family

ID=49778401

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201492177A EA034549B1 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
EA202090044A EA202090044A1 (en) 2012-06-29 2013-06-28 PURIFICATION OF IDURONATE-2-SULPHATASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090044A EA202090044A1 (en) 2012-06-29 2013-06-28 PURIFICATION OF IDURONATE-2-SULPHATASE

Country Status (38)

Country Link
US (6) US9051556B2 (en)
EP (2) EP3441398A1 (en)
JP (4) JP6171007B2 (en)
KR (5) KR101380740B1 (en)
CN (3) CN107596357A (en)
AR (1) AR091647A1 (en)
AU (3) AU2013282395C1 (en)
BR (1) BR112014032567B1 (en)
CA (2) CA2877517C (en)
CL (1) CL2014003567A1 (en)
CO (1) CO7240396A2 (en)
CR (1) CR20140588A (en)
CY (1) CY1121519T1 (en)
DK (1) DK2867245T3 (en)
DO (1) DOP2014000294A (en)
EA (2) EA034549B1 (en)
ES (1) ES2689468T3 (en)
GT (1) GT201400303A (en)
HK (4) HK1209431A1 (en)
HR (1) HRP20181897T1 (en)
HU (1) HUE040769T2 (en)
IL (4) IL236315A (en)
LT (1) LT2867245T (en)
MX (3) MX336715B (en)
MY (3) MY180287A (en)
NZ (3) NZ743910A (en)
PE (1) PE20150720A1 (en)
PH (3) PH12014502871B1 (en)
PL (1) PL2867245T3 (en)
PT (1) PT2867245T (en)
RS (1) RS58005B1 (en)
SG (2) SG11201408761VA (en)
SI (1) SI2867245T1 (en)
TR (1) TR201815811T4 (en)
TW (2) TWI587869B (en)
UA (1) UA121959C2 (en)
WO (1) WO2014005014A2 (en)
ZA (2) ZA201409397B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
KR101158673B1 (en) 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
AU2017316955B2 (en) 2016-08-25 2022-03-03 Jcr Pharmaceuticals Co., Ltd. Method for producing antibody fusion protein
CN106282231B (en) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 Construction method and application of mucopolysaccharide storage disease type II animal model
CN106428420B (en) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 A method of being used for the installation of super-container vessel crack arrest steel hatch coaming
MX2020002918A (en) 2017-10-02 2020-07-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes.
JP7458404B2 (en) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド Purification of iduronic acid-2-sulfatase immunoglobulin fusion protein
CN116670270A (en) * 2020-10-23 2023-08-29 阿雷克森制药公司 Method for controlling Total Sialic Acid Content (TSAC) during alkaline phosphatase manufacture

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (en) 1988-01-07 1988-01-07 Novo Industri As ENZYMES
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (en) 1995-07-26 1997-01-30 Behringwerke Ag Method for characterizing the glycosylation of glycoproteins and for in-vitro determination of the bioavailability of glycoproteins
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP1171615B1 (en) 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
JP2002017376A (en) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk Secretory protein or membrane protein
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
CA2511520A1 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
ES2687671T3 (en) 2004-01-30 2018-10-26 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A to reduce galatosyl sulfatide levels in a subject
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
PT1885753E (en) 2005-06-03 2011-10-06 Ares Trading Sa Production of recombinant il-18 binding protein
WO2007108955A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (en) 2007-06-29 2010-04-28 キヤノン株式会社 Process cartridge and electrophotographic image forming apparatus
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
SI2485761T1 (en) 2009-10-09 2019-05-31 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (en) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 Method for producing recombinant lysosomal enzymes using gene knockout cells
EP3964229A1 (en) 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
NZ605871A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
AR082319A1 (en) 2010-07-22 2012-11-28 Biomarin Pharm Inc PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES
JP5865839B2 (en) * 2010-09-28 2016-02-17 共立製薬株式会社 Mucosal adjuvant composition
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (en) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (en) * 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
KR20190062745A (en) 2017-11-29 2019-06-07 주식회사 위니플 Shopping mall mobile app builder

Also Published As

Publication number Publication date
TW201410868A (en) 2014-03-16
KR20190064542A (en) 2019-06-10
AU2018200230B2 (en) 2020-01-02
AU2013282395C1 (en) 2016-03-24
JP2018121645A (en) 2018-08-09
DOP2014000294A (en) 2015-03-15
CA3008945A1 (en) 2014-01-03
EP2867245A2 (en) 2015-05-06
TWI553120B (en) 2016-10-11
US11530393B2 (en) 2022-12-20
US20140004096A1 (en) 2014-01-02
US20210317426A1 (en) 2021-10-14
HK1209767A1 (en) 2016-04-08
SG10201703489VA (en) 2017-05-30
PH12015502408A1 (en) 2018-03-26
CN107596358A (en) 2018-01-19
TR201815811T4 (en) 2018-11-21
EA202090044A1 (en) 2020-07-31
EP3441398A1 (en) 2019-02-13
SI2867245T1 (en) 2018-12-31
WO2014005014A3 (en) 2014-02-27
JP2016119911A (en) 2016-07-07
PE20150720A1 (en) 2015-05-16
BR112014032567A2 (en) 2017-08-01
IL261264B (en) 2021-10-31
IL236315A (en) 2016-11-30
JP2020105209A (en) 2020-07-09
HRP20181897T1 (en) 2019-01-11
RS58005B1 (en) 2019-02-28
US20170073652A1 (en) 2017-03-16
MX2015000190A (en) 2015-04-08
PL2867245T3 (en) 2019-02-28
AU2016200469B2 (en) 2017-10-12
IL236315A0 (en) 2015-02-26
CY1121519T1 (en) 2020-05-29
AU2016200469A1 (en) 2016-02-18
HK1249027A1 (en) 2018-10-26
EA034549B1 (en) 2020-02-19
AU2013282395A1 (en) 2015-01-29
CN104583225A (en) 2015-04-29
PH12015502408B1 (en) 2018-03-26
NZ703093A (en) 2017-08-25
CN107596357A (en) 2018-01-19
SG11201408761VA (en) 2015-01-29
KR20200143339A (en) 2020-12-23
KR101380740B1 (en) 2014-04-11
PH12014502871A1 (en) 2015-02-23
CO7240396A2 (en) 2015-04-17
KR20140002451A (en) 2014-01-08
US10344270B2 (en) 2019-07-09
ES2689468T3 (en) 2018-11-14
TWI587869B (en) 2017-06-21
MX2019008914A (en) 2019-09-26
CA2877517A1 (en) 2014-01-03
EP2867245A4 (en) 2016-03-09
WO2014005014A2 (en) 2014-01-03
CL2014003567A1 (en) 2015-04-24
HK1209431A1 (en) 2016-04-01
EP2867245B1 (en) 2018-09-12
MX336715B (en) 2016-01-28
TW201703794A (en) 2017-02-01
ZA201803289B (en) 2021-04-28
GT201400303A (en) 2017-08-31
LT2867245T (en) 2018-11-12
AR091647A1 (en) 2015-02-18
PH12020500027A1 (en) 2021-03-15
ZA201409397B (en) 2019-10-30
US9051556B2 (en) 2015-06-09
AU2013282395B2 (en) 2015-12-03
NZ733366A (en) 2019-12-20
US20150313972A1 (en) 2015-11-05
UA121959C2 (en) 2020-08-25
CR20140588A (en) 2015-04-06
KR20220002227A (en) 2022-01-06
HUE040769T2 (en) 2019-03-28
US20190359958A1 (en) 2019-11-28
HK1249026A1 (en) 2018-10-26
BR112014032567B1 (en) 2022-09-13
IL261264A (en) 2018-10-31
CA2877517C (en) 2018-07-31
US9492511B2 (en) 2016-11-15
US20240043817A1 (en) 2024-02-08
JP6171007B2 (en) 2017-07-26
MY180287A (en) 2020-11-27
JP6505629B2 (en) 2019-04-24
MY157087A (en) 2016-04-19
MX366906B (en) 2019-07-30
PT2867245T (en) 2018-11-26
IL287057A (en) 2021-12-01
JP2015523072A (en) 2015-08-13
KR20140004603A (en) 2014-01-13
AU2018200230A1 (en) 2018-02-01
NZ743910A (en) 2019-12-20
MY192068A (en) 2022-07-25
IL248727A0 (en) 2017-01-31
DK2867245T3 (en) 2018-11-26
PH12014502871B1 (en) 2015-02-23

Similar Documents

Publication Publication Date Title
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
MX2020003798A (en) Methods for purification of arylsulfatase a.
NZ743008A (en) Compositions and methods for internalizing enzymes
BR112015019879A2 (en) SPECIES COMPOSITIONS OF MODULATED LYSINE VARIANTS AND METHODS FOR THE PRODUCTION AND USE OF THEM
IN2012DN00801A (en)
EA201391157A1 (en) PCTA9 ANTAGONISTS
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
EA201492185A1 (en) METHOD OF OBTAINING RECOMBINANT IDURONAT-2-SULFATASE
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
FI20115328A0 (en) New cutinases, their production and uses
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
EA201590778A1 (en) CLEANING OF COMBINED GALACTOCEREBROZIDE-β-GALAKTOSIDASE OF MAN
MX2015010887A (en) Formulations and methods for increased recombinant protein production.
MX341733B (en) Purification of cell culture derived alpha1 protease inhibitor.
MX2021016092A (en) Methods for protein purification.
EA201990926A1 (en) FVIII CLEANING PROCESS
RU2012143225A (en) METHOD FOR ISOLATION AND CLEANING OF AN IMMOBILIZED ENZYME
TH160179B (en) Purification of idylronate-2-sulfatase
FI20115976A0 (en) Use of a proteolytic enzyme
TH160179A (en) Purification of idylronate-2-sulfatase
MX2014004027A (en) Zymogen activators.

Legal Events

Date Code Title Description
MD4A Opposition filed against granted eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

LC4A Partial administrative revocation of a eurasian patent (b2)